Where Ideas grow
Bruno Sarmento
Group leader

Bruno Sarmento is Principal Investigator at INEB/i3S, Institute of Biomedical Engineering/Institute for Investigation and Innovation in Health, University of Porto, and Assistant Professor at IUCS, Instituto Universitário de Ciências da Saúde, Portugal.

He graduated in Pharmaceutical Sciences at the University of Porto (UP) in 2002 and completed a PhD in Pharmaceutical Nanotechnology at UP in 2007, in collaboration with Queen’s University (CA), University of Copenhagen (DK) and University of Santiago de Compostela (ES). From 2007 to 2012 he held a Post-Doc position at UP, in collaboration with the University of Copenhagen. In 2008 he was appointed Assistant Professor at IUCS. He also co-founded Inovapotek in 2008, and is member of its advisory board. In 2012 he became Associated Researcher at INEB, where established an independent team. He was appointed as Assistant Researched at INEB/i3S in 2016. He is Visiting Professor of the Post-Graduate School, UniOeste (BR) and Visiting Research Professor at Queen’s University, Belfast (UK).

So far, he has supervised/co-supervised 11 Post-Docs (7 completed), 38 PhD students (20 completed) and 36 MSc students (30 completed), and 11 researcher assistants. He attracted direct competitive funding worth more than 8 M€, at national and international levels.

His current research is focused on the development of functionalized nanomedicines and their application in the pharmaceutical and biomedical fields. In particular, nanoformulations of biopharmaceutical drugs with interest in diabetes, cancer and infectious diseases. He has also specialized in mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. He published more than 320 papers in international peer reviewed (ISI) journals, most in top journals (Q1 in Pharmaceutical Sciences; Q1 in Nanoscience and Nanotechnology; total citations in Scopus 8418; H-index 46 and in GoogleScholar 11820; H-index 51), 45 book chapters and more than 250 proceedings. He edited 5 books, participated in more than 50 invited/selected talks in national and international meetings and was awarded several distinctions. He is editor of European Journal of Pharmaceutical Sciences, and member of the Editorial Advisory Board of 11 international journals, including the prestigious Journal of Controlled Release and Expert Opinion on Drug Delivery. Bruno Sarmento is the Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society. He has acted as referee for top-ranked journals in his area of expertise, and for international funding agencies: FNRS (BE), Inserm (FR), CNCS (RO), FCT (PT), Foncyt (ARG), CNPq (BR) and European Commission. In addition to being a partner in several research projects, he was the PI of competitively funded projects (FCT, Gilead and CESPU), PI of different bilateral collaborative projects between Portugal (FCT) and foreigner funding agencies as well as partner of several European projects funded by European Commission.

Selected Publications

Costa A., de Souza Carvalho-Wodarz C., Seabra V., Sarmento B., Lehr C.,
Triple co-culture of human alveolar epithelium, endothelium and macrophages for studying the interaction of nanocarriers with the air-blood barrier. Acta Biomaterialia91:235-247, 2019. [Journal: Article] [IF: 6,6 (*)]
DOI: 10.1016/j.actbio.2019.04.037 SCOPUS: 85064521323. .

Lin K., Zhang D., Macedo M., Cui W., Sarmento B., Shen G.,
Advanced Collagen-Based Biomaterials for Regenerative Biomedicine. Advanced Functional Materials29(3):, 2019. [Journal: Review] [IF: 15,6 (*)]
DOI: 10.1002/adfm.201804943 SCOPUS: 85057216174. .

Sousa F., Cruz A., Pinto I., Sarmento B.,
Nanoparticles provide long-term stability of bevacizumab preserving its antiangiogenic activity. Acta Biomaterialia78:285-295, 2018. [Journal: Article] [CI: 2] [IF: 6,6]
DOI: 10.1016/j.actbio.2018.07.040 SCOPUS: 85050301441. .

Macedo M., Araújo F., Martínez E., Barrias C., Sarmento B.,
iPSC-Derived Enterocyte-like Cells for Drug Absorption and Metabolism Studies. Trends in Molecular Medicine24(8):696-708, 2018. [Journal: Review] [CI: 2] [IF: 11,0]
DOI: 10.1016/j.molmed.2018.06.001 SCOPUS: 85048879330. .

Lechanteur A., das Neves J., Sarmento B.,
The role of mucus in cell-based models used to screen mucosal drug delivery. Advanced Drug Delivery Reviews124:50-63, 2018. [Journal: Review] [CI: 16] [IF: 15,5]
DOI: 10.1016/j.addr.2017.07.019 SCOPUS: 85026524492. .

Araújo F., das Neves J., Martins J., Granja P., Santos H., Sarmento B.,
Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals. Progress in Materials Science89:306-344, 2017. [Journal: Review] [CI: 10] [IF: 23,8]
DOI: 10.1016/j.pmatsci.2017.05.001 SCOPUS: 85020029869. .

Lozoya-Agullo I., Araújo F., González-Álvarez I., Merino-Sanjuán M., González-Álvarez M., Bermejo M., Sarmento B.,
Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B coculture models to predict intestinal and colonic permeability compared to Caco-2 monoculture. Molecular Pharmaceutics14(4):1264-1270, 2017. [Journal: Article] [CI: 16] [IF: 4,6]
DOI: 10.1021/acs.molpharmaceut.6b01165 SCOPUS: 85019014428. .

Bauleth-Ramos T., Shahbazi M., Liu D., Fontana F., Correia A., Figueiredo P., Zhang H., Martins J., Hirvonen J., Granja P., Sarmento B., Santos H.,
Nutlin-3a and Cytokine Co-loaded Spermine-Modified Acetalated Dextran Nanoparticles for Cancer Chemo-Immunotherapy. Advanced Functional Materials27(42):, 2017. [Journal: Article] [CI: 10] [IF: 13,3]
DOI: 10.1002/adfm.201703303 SCOPUS: 85028762962. .

Cunha-Reis C., Machado A., Barreiros L., Araújo F., Nunes R., Seabra V., Ferreira D., Segundo M., Sarmento B., das Neves J.,
Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs. Journal of Controlled Release243:43-53, 2016. [Journal: Article] [CI: 24] [IF: 7,8]
DOI: 10.1016/j.jconrel.2016.09.020 SCOPUS: 84990849820. .

Araújo F., Shrestha N., Gomes M., Herranz-Blanco B., Liu D., Hirvonen J., Granja P., Santos H., Sarmento B.,
In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy. Nanoscale8(20):10706-10713, 2016. [Journal: Article] [CI: 18] [IF: 7,4]
DOI: 10.1039/c6nr00294c SCOPUS: 84971265278. .